LLY vs NBTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NBTX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational instability. The valuation is extreme, with a Price/Sales ratio of 47.36 and a negative Price/Book ratio (-19.23), suggesting the company is trading on speculative future catalysts rather than current assets or earnings. While the stock has seen a massive 1-year price surge of 855.9% and maintains a 'strong_buy' analyst consensus, the deterministic data reveals a company with negative equity and unsustainable margins. The disconnect between the technical momentum and the underlying financial decay presents a high-risk profile.
Compare Another Pair
Related Comparisons
LLY vs NBTX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Nanobiotix S.A. (NBTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.